Ipsen announced the presentation of new late-breaking results from the ELATIVE® Phase III trial and two real-world studies at the European Association for the Study of the Liver (EASL)… read more.
ImmunityBio announced results from two indirect treatment comparison (ITC) analyses presented at the 2026 American Urological Association (AUA) Annual Meeting evaluating nogapendekin alfa inbakicept-pmln (NAI, Anktiva) plus Bacillus Calmette–Guérin (BCG)… read more.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, announced that final data from the Phase 3 AcceleRET-Lung clinical trial of… read more.
Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30,… read more.
At the 2026 ASCO Annual Meeting, Boehringer Ingelheim presented new data from across its oncology clinical development program, including patient-reported outcomes (PROs) for HERNEXEOS® (zongertinib tablets) in HER2… read more.
Novo Nordisk announced data demonstrating that Wegovy (semaglutide 2.4 mg and 7.2 mg) delivers substantial and consistent weight-loss results for women with obesity across reproductive life stages, from… read more.
MetaVia announced that a late-breaking abstract highlighting DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors for the treatment of obesity, has… read more.
United Therapeutics Corporation announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20,… read more.
Cytokinetics, Incorporated announced the presentation of new data reinforcing the clinical profile of Myqorzo (aficamten) at the European Society of Cardiology (ESC) Heart Failure 2026 Congress. The presentations… read more.
EAHP Congress Highlights The timing of immunotherapy administration influences treatment effectiveness, with morning treatment associated with significantly better survival outcomes, according to new real-world data presented at the… read more.
EAHP Congress Highlights The use of autologous serum eye drops (ASED) was associated with promising real-world outcomes in patients with severe ocular surface diseases refractory to conventional treatment,… read more.
Viking Therapeutics announced that it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
